BioSyent Inc. (TSXV:RX)

Market Cap	171.57M +30.6%
Revenue (ttm)	45.98M +20.1%
Net Income	9.04M +15.5%
EPS	0.78 +17.5%
Shares Out	11.44M
PE Ratio	19.13
Forward PE	16.00
Dividend	0.22 (1.47%)
Ex-Dividend Date	May 29, 2026

Volume	8,996
Open	15.51
Previous Close	15.00
Day's Range	15.00 - 15.51
52-Week Range	10.65 - 15.80
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2025, BioSyent's revenue was 43.05 million, an increase of 22.90% compared to the previous year's 35.03 million. Earnings were 9.01 million, an increase of 23.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error